Selectis Health ( (GBCS) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Selectis Health, Inc. has filed a Form 12b-25 to notify investors that it will delay its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The filing confirms that the affected report is the company’s annual Form 10-K (Yearly Report), which covers its full-year financial performance.
The company cites the need for additional time to review and prepare certain information related to its audited financial statements as the main reason for the delay. Management states that filing the Form 10-K (Yearly Report) on time would have required unreasonable effort and expense, but does not mention any auditor changes, control failures, or special committee investigations.
Selectis Health expects to file the overdue Form 10-K (Yearly Report) within the grace period allowed under SEC Rule 12b-25. For an annual report, this means the company intends to submit the filing no later than the fifteenth calendar day after the original due date, signaling that management views the delay as temporary and manageable.
The company indicates that it does not anticipate any significant change in operating results compared with the prior fiscal year’s corresponding period. While detailed numbers are not yet available, this statement suggests that the upcoming audited figures should be broadly in line with previous performance, though investors should remember that such expectations are forward-looking and subject to revision once the Form 10-K (Yearly Report) is finalized.
Selectis Health affirms that all other required periodic reports over the past 12 months have been filed, underscoring continued regulatory compliance aside from this single late annual report. The notification is signed on behalf of the company by Chief Executive Officer Adam Desmond, dated March 31, 2026, signaling executive-level oversight of the filing delay and the steps being taken to complete the annual report.
The most recent analyst rating on (GBCS) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Selectis Health stock, see the GBCS Stock Forecast page.
Spark’s Take on GBCS Stock
According to Spark, TipRanks’ AI Analyst, GBCS is a Underperform.
The overall stock score for GBCS is primarily impacted by its weak financial performance, characterized by negative profitability and high leverage. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events does not affect the score.
To see Spark’s full report on GBCS stock, click here.
More about Selectis Health
Selectis Health, Inc. is a U.S.-based company that files reports with the Securities and Exchange Commission and is listed under SEC File Number 0-15415 and CUSIP 816291108. The firm operates in the healthcare sector and is required to submit annual and periodic reports under the Securities Exchange Act of 1934.
Average Trading Volume: 3,131
Technical Sentiment Signal: Buy
Current Market Cap: $12.67M
See more data about GBCS stock on TipRanks’ Stock Analysis page.